Highly bioavailable curcumin in COVID-19 with no symptoms.
- Conditions
- Coronavirus infection (COVID-19)
- Registration Number
- JPRN-jRCTs051210176
- Lead Sponsor
- Hasegawa Koji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 160
(1) Within 5 days after being diagnosed as COVID-19 by PCR test or antigen test (described in the guideline for medical treatment of COVID-19, 5.3 th edition (Ministry of Health, Labor and Welfare)).
(2) Receiving no oxygen therapy and SpO2 is 96% or higher.
(3) Body temperature is less than 37.5 degree Celsius.
(4) Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1.
(5) Age 20 years or older, both gender
(6) Written informed consent was obtained.
(1) Patients taking antithrombotic drugs (anticoagulants, EPA preparations, prostacyclin preparations)
(2) Patients with a history of cerebral hemorrhage
(3) Patients receiving oxygen therapy at home or dialysis
(4) Patients with end-staged cancer
(5) Patients taking steroids on a regular basis
(6) Regular users of healthy foods containing curcumin
(7) Patients with a history of allergies to curcumin
(8) Pregnant women and those who are breastfeeding or may become pregnant
(9) Patients who are scheduled to recieve neutralizing antibody therapy or anti-virus drugs.
(10) Those who are judged by the principal investigator or the research coordinator to be inappropriate for participation in this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method